Upgrade to SI Premium - Free Trial

Oppenheimer Starts Collegium Pharmaceutical (COLL) at Outperform

September 23, 2026 6:11 AM
Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Outperform rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments New Coverage